Sex Hormone-regulated CMG2 Is Involved in Breast and Prostate Cancer Progression

Background/Aim: Capillary morphogenesis gene 2 (CMG2) is involved in prostate and breast cancer progression. This study aimed to investigate sex hormone receptor-mediated regulation of CMG2 in breast and prostate cancer, and its implication in disease progression. Materials and Methods: Expression o...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genomics & proteomics 2022-11, Vol.19 (6), p.703-710
Main Authors: FANG, ZIQIAN, KILLICK, CHARLOTTE, HALFPENNY, CERITH, FREWER, NATASHA, FREWER, KATHRYN A., RUGE, FIONA, JIANG, WEN G., YE, LIN
Format: Article
Language:English
Subjects:
Androgen receptors
Breast cancer
Deprivation
DNA microarrays
Estrogen receptors
Morphogenesis
Overexpression
Prostate cancer
Receptors
Sex hormones
Transcriptomes
Tumor cell lines
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: Capillary morphogenesis gene 2 (CMG2) is involved in prostate and breast cancer progression. This study aimed to investigate sex hormone receptor-mediated regulation of CMG2 in breast and prostate cancer, and its implication in disease progression. Materials and Methods: Expression of CMG2, oestrogen receptor (ER) and androgen receptor (AR) was determined in breast and prostate cancer cell lines, respectively, using real-time quantitative PCR (QPCR) and western blot. Association between CMG2 and sex hormone receptors was analysed in a number of transcriptome datasets. Immunochemical staining was performed in tissue microarrays of breast cancer (BR1505D) and prostate cancer (PR8011A). CMG2 expression was determined in 17β-oestradiol treated breast cancer cells and AR over-expressing prostate cancer cells. Results: CMG2 was found to be inversely correlated with sex hormone receptors in breast and prostate cancer. Lower expression of CMG2 was associated with a poor prognosis in ER (+) breast cancer but not ER (−) tumours. Both ER (+) breast cancer cell lines and AR (+) prostate cancer cell lines presented lower expression of CMG2, which was increased following sex hormone deprivation. Exposure to 17-β-oestradiol and AR over-expression repressed CMG2 expression in breast cancer and prostate cancer cell lines, respectively. Conclusion: CMG2 is inversely correlated with ER and AR status in breast and prostate cancer, respectively. ER and AR mediate repression of CMG2 expression in corresponding cancerous cells.
ISSN:1109-6535
1790-6245
DOI:10.21873/cgp.20353